GoDubai
  
  
  
  
Citylife > Press Release
  Home Contact us Add to Favourites
Most Recent Postings
More Press Releses
Featured Sections

Event Finder
A daily roundup of exhibitions, promotions and other events in Dubai and the rest of the Emirates.
Submit an Event
Latest Dubai Press Releases >>

 
  Share
  • Sharp increase in net sales to nearly 18.1 billion euros
  • (+15.7 per cent in currency-adjusted terms; +13.9 per cent in 
  • euro terms)
  • Operating income rises significantly to around 3.5 billion euros
  • Return on net sales of 19.3 per cent
  • Strengthened animal health business successful
  • Boehringer Ingelheim Middle East, Turkey, Africa (META) achieved a sales growth of 10% in 2017

United Arab Emirates, 25 April 2018 – The research-driven pharmaceutical company Boehringer Ingelheim can look back on a very successful 2017 financial year. All businesses contributed to net sales growth. R&D expenditure exceeded three billion euros, around 2.7 billion euros of which was in the human pharmaceuticals area alone. “There are still more questions than answers in medicine. We want to continue putting all our efforts into tackling the challenges in research. A high level of investment in R&D therefore reflects our corporate identity,” explained Hubertus von Baumbach, Chairman of the Board of Managing Directors. 

Last year, Boehringer Ingelheim generated net sales of nearly 18.1 billion euros, representing an increase of 15.7 per cent in currency-adjusted terms (+13.9 per cent in euro terms). Adjusted for all the one-off effects that have resulted from the business swap with Sanofi, the company recorded currency-adjusted net sales growth of 6.1 per cent (+4.4 per cent in euro terms). With operating income of around 3.5 billion euros, the return on net sales came to 19.3 per cent. The company employed an average of approximately 50,000 people worldwide in 2017. 

Enrique Manzoni, Regional Managing Director – Middle East, Turkey, Africa (META) at Boehringer Ingelheim said, “Boehringer Ingelheim's consistent strong performance across the META region is backed by a strong and excellent execution of the company's business strategy and a solid business model that reflects its position as the fastest growing pharmaceutical company in the region in our Human Pharma business. Our financial and operational performance mirrors the company's consistent commitment towards meeting the region's unmet medical needs by delivering innovative initiatives across a number of key therapeutic areas such as type 2 diabetes and stroke.” 

“The region is well poised to be the next growth engine of global pharmaceutical sales. To that extent, we continue to work with our partners to further support and enhance the healthcare infrastructure that ultimately aims at providing integrated healthcare services and solutions. In 2017, we have been able to launch 10 products in addition to registering 38 products across the region,” added Manzoni. 

In addition, Christoph Raab, Head of Finance and Administration at Boehringer Ingelheim META said, “In the META, we have achieved a 10% sales growth during 2017 compared to the same period last year. Moreover, the company's Human Pharma portfolio recorded a 13.1% growth, while the Animal Health business achieved a 3.6% growth. Our top performing markets included the United Arab Emirates, Saudi Arabia and Turkey“.  

Worldwide Net sales growth in all businesses
Boehringer Ingelheim experienced organic growth across all business areas last year. “Our human pharmaceuticals business in particular exceeded our expectations,” emphasised Michael Schmelmer, Member of the Board of Managing Directors responsible for Finance. “The main growth drivers here were our business in the US market and emerging markets.” 

Major success with human pharmaceuticals globally 
In the human pharmaceuticals business, Boehringer Ingelheim last year succeeded in generating net sales of more than one billion US dollars each with six medicines that focused on respiratory illnesses such as chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF), the anticoagulant reversal agent, type 2 diabetes, as well as the treatment of hypertension.

Overall, net sales from human pharmaceuticals grew by 6.9 per cent in currency-adjusted terms to more than 12.6 billion euros (+5.0 per cent in euro terms). This growth outpaced the market. The human pharmaceuticals business therefore contributed around 70 per cent of total net sales. 

2017 was also a very successful year for Boehringer Ingelheim in R&D. The company accomplished the transfer of 13 new active ingredients to clinical studies as first-in-man applications. The company is thus focusing on the areas of cardiometabolic diseases, oncology, respiratory diseases, diseases of the central nervous system and immunology. “We have an extremely competitive pipeline with 80 development projects,” said von Baumbach. “This provides us with strong future prospects for sustainable business development and particularly for innovation that benefits patients.”

As a result of the additional net sales brought about by the transaction, net sales in animal health have more than doubled to 3.9 billion euros. The two parasiticides generated the largest share of net sales: the beef flavoured chews for dogs is the best-selling product at 546 million euros, followed by flea and tick treatment at 381 million euros. Overall, Boehringer Ingelheim generated around 22 per cent of its total net sales in the animal health business. “We have made good progress with a challenging and complex integration process,” explained von Baumbach. “Our employees deserve our unreserved recognition and our gratitude for this – due in no small part to their commitment, we are now a competitive player for the future in the animal health business. We are outstandingly positioned for medical breakthroughs that will make animal diseases controllable through prevention.”

The biopharmaceutical contract manufacturing business grew by 10.7 per cent in currency-adjusted terms last year to 678 million euros and contributed four per cent to total net sales. 

Holistic approaches for humans and animals
A key strategic objective of Boehringer Ingelheim globally is to develop holistic approaches that benefit patients, both human and animal. Digital projects that focus on patients are an example of this. Boehringer Ingelheim recently established the BI X digital laboratory and increased the Boehringer Ingelheim Venture Fund from 100 to 250 million euros, 50 million of which is intended for digital innovation alone. “At the same time, we always ask ourselves how we can further improve the lives of patients and relatives as well as the treatment options for doctors,” explained Schmelmer.

Outlook for 2018
For the current financial year, Boehringer Ingelheim globally is expecting slight growth in net sales on a comparable basis.

“In the META region, we are well on our way to continue achieving growth levels in 2018, in line with our overall business strategy and leveraging synergies across the region. In 2018, the company is expecting 33 market authorizations throughout the wider META region. In addition, we are also expanding our footprint in the Sub Saharan Africa with key investments in driving access to healthcare programs to develop innovative solutions,” concluded Manzoni.

 



Posted by : GoDubai Editorial Team
Viewed 5087 times
Posted on : Wednesday, April 25, 2018  
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of GoDubai.com.
Previous Story : Region's happy workplaces revealed
Next Story : Bosch Blazing New Trails in Mobility and Environmental Protection
Email this article Print this article

Share this article with your friends and followers
NewsVine

Comments

Back to Top  
Most Viewed Press Release posted in the last 7 days
Skyline Book Fair 2018
The Bremont Waterman
Holiday hair: The best product to keep your locks smelling fresh and protected
ServeU to Take Huge Leap Forward with Smart Cleaning Robots
Emirates celebrates inaugural flight to London Stansted
Chronoswiss' Exclusive Limited Edition Flying Regulator Marks 31st Anniversary o...
Blackberry Key2: An Icon Reborn
Marchon Eyewear Summer 2018 Collections
The Future Takes The Past Tense
CSR Initiatives by Malabar Gold & Diamonds continues in full strength
du Distributes Eid Gifts at Al Jalila Children's Hospital
Consulate General of India Mr. Vipul came as CHIEF GUEST at the blood donation c...
DWTC events drive AED 12.7bn in economic value for Dubai, fuelling record 3.3% c...
Al-Futtaim ACE celebrates Eid with exciting offers and activities
24 hour Mega Sale at Dalma Mall!
Beauty on the Go
Purify Your Skin with Skin Republic
A Sparkling Gift Guide for Eid al-Fitr by Mouawad
Filorga introduces two new additions to its UV-BRONZE range offering a comprehen...
Al Ghandi Auto brings the most Affordable Electric Vehicle - Chevrolet Bolt EV -...
Skin Hydration is one of the primary challenges our skin faces in the UAE
Rapid renewal of smartphone portfolio brings next generation Nokia 5 and Nokia ...
New open-air member of the AMG GT family
Hamdan Bin Mohammed Heritage Center distributes Eidia on first day of Eid
Abu Dhabi Treats Eid Al Fitr Visitors to Shopping Bonanza with 90% Discounts Acr...
iVOOMi Smartphones Enter the UAE Market Exclusively on SOUQ.com
Hamilton Jazzmaster Maestro Auto Chrono
The Summer Just Got Sweeter with the New Palm Candy Collection from Max
Captivate Your Senses with Marks & Spencer's Exclusive Oud Collection
Crowe Horwath announces global rebrand to “Crowe” Sometimes a smart decision i...
Tissot Chrono XL Tour de France Special Edition Cycling just got big
Dubai to Witness the First Ever Jewellery Season With Grand Discounts and Surprises
Stylish men's watch - BU4018-11H - with rose gold case and black dial is a real ...
Great Moments Manero Flyback accompanies Swiss National Soccer Team To Russia
The Rado True Phospho wins 2018 Good Design Award®
The Lacoste Moon Collection
Axalta and Mohamed Naser Al Sayer Toyota Service Body Shop Go Green in Kuwait
Splash's ‘Life After Fashion' Campaign Breathes New Life into Old Garments
Eid Al Fitr, the FIFA World Cup and much more at Danat Al Ain Resort
Zulekha Hospital surgeon saves patient from losing normal hand functions
Eight Tips to Avoid Overindulging this Eid
Summer Romance in the air with Max's new seasonal Collection
Celebrate Eid Al-Fitr with Emaar Entertainment
Medeor 24x7 International Hospital, Al Ain - Quran Competition
DHA Hospitals becomes first in the Emirate to use clip technology by angiography...
Dubai Summer Surprises Calendar of Events Revealed
Ibn Battuta Mall debuts three international kids' shows this Eid Al Fitr and DSS
Celebrate Eid Al Fitr at Dubai Festival City
Liali Jewellery gets the Capillary Technologies boost to enhance customer engagement
Mido Baroncelli - A Trilogy of Limited Editions